Ting-Ting Wang

Ting-Ting Wang

Auto-generated profile, based on publicly available information

Ting-Ting Wang

Sun Yat-sen University Cancer Center 1 Guangzhou

Research Focus & Metrics

Academic Career Length

10Years (2017-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
30 October 2026 in Cancer Research
Verified
Journal Article
Closed access
TWTing-Ting Wang
Ting-Ting Wang
WKWei-Shuai Kong
Wei-Shuai Kong
JLJia-Jun Li
Jia-Jun Li
YQYing-Yu Qiu
Ying-Yu Qiu
RHRen-Ze Huang
Ren-Ze Huang
HJHuai-Qiang Ju
Huai-Qiang Ju
Clinical outcomes are often suboptimal in patients with colorectal cancer treated with neoadjuvant chemotherapy (NAC). A key determinant of the response to NAC is the functional state of tumor-infiltrating immune cells. Understanding how NAC reshapes the immunologic landscape will be essential for refining patient stratification and identifying effective combination treatment strategies. In this study, we analyzed paired samples before and after NAC treatment by single-cell RNA sequencing (scRNA-seq), revealing that NAC treatment significantly reshaped the immune microenvironment. Tumors from NAC nonresponders featured increased immunosuppressive M2-like macrophage infiltration, which correlated with elevated phosphatidylserine-specific phospholipase A1 (PLA1A). Mechanistically, PLA1A hydrolyzed phosphatidylserine (PS) exposed by chemotherapy to elevate lysophosphatidylserine (LysoPS), which activated the P2ry10 receptor and downstream signaling to promote M2-like macrophage polarization. Importantly, pharmacologic inhibition of PLA1A by cilengitide synergized with chemoimmunotherapy to suppress tumor progression in murine models. Clinically, high plasma PLA1A levels negatively correlated with responses to chemoimmunotherapy. Collectively, these findings reveal a chemotherapy-driven metabolic axis that induces an immunosuppressive milieu by increasing LysoPS release. This axis highlights PLA1A as a therapeutic target to mitigate immunosuppression and improve chemoimmunotherapy efficacy. Significance: Chemotherapy-resistant colorectal cancer elevates PLA1A to induce anti-inflammatory macrophage polarization, supporting the potential of PLA1A as a therapeutic target for enhancing chemoimmunotherapy efficacy and as a biomarker of treatment response.